To report the response of participants switching from ranibizumab to aflibercept treatment for neovascular age-related macular degeneration (nAMD) requiring further anti-vascular endothelial growth factor treatment.
In this retrospective case review of 68 participants treated in a single hospital, all participants, prior to switching, received ranibizumab injections only. Best-corrected visual acuity (BCVA), clinical examination, and optical coherence tomography (OCT) were performed at each visit. Active nAMD was defined as persistent intraretinal or subretinal fluid on OCT. Participants had their first aflibercept injection at baseline and 2 more injections at 2 monthly intervals. Afterwards, they were followed up every 6-8 weeks and given injections as needed. The main outcome measures were visual acuity and the OCT central retinal thickness (CRT), average thickness (AT), and total macular volume (TMV).
The BCVA at baseline visit was 0.57 ± 0.33 log MAR and the final BCVA was 0.54 ± 0.37 log MAR (p = 0.215). The CRT mean change was -75.6 ± 85.6 (p = 0.001), the AT mean change was -24.2 ± 27.2 (p = 0.001), and TMV mean change was -0.69 ± 0.78 (p = 0.001). There were no significant ophthalmic complications related to treatments.
Intravitreal aflibercept improved anatomic outcomes (as measured by OCT) in eyes with nAMD that were previously treated with intravitreal ranibizumab and were still active. There was no statistically significant difference in logMAR visual acuity in participants who switched to aflibercept with a follow-up of at least 6 months.
Eur J Ophthalmol 2017; 27(3): 342 - 345
Article Type: ORIGINAL RESEARCH ARTICLE
AuthorsLauren Van Lancker, Robert Petrarca, Kyros Moutsouris, Panos Masaoutis, George Kampougeris
- • Accepted on 15/09/2016
- • Available online on 03/10/2016
- • Published in print on 11/05/2017
This article is available as full text PDF.
- Van Lancker, Lauren [PubMed] [Google Scholar]
- Petrarca, Robert [PubMed] [Google Scholar]
- Moutsouris, Kyros [PubMed] [Google Scholar]
- Masaoutis, Panos [PubMed] [Google Scholar]
- Kampougeris, George [PubMed] [Google Scholar] , * Corresponding Author (firstname.lastname@example.org)
Moorfields Eye Hospital NHS Trust, Croydon University Hospital, Surrey - UK